



A webinar series brought to you by  
Schwabe Pharma Asia Pacific



web-BRAIN-nar  
*BRidging Asia In Neurocognition*

Date: 29 July 2021 (Thursday)

Time: 6.00pm – 7.00pm (SG Time)

- Introduction (5mins)
- Presentation by A/Prof. Nagaendran Kandiah (30mins)
- Q&A (25mins)

Panelists: Dr Chan Yee Fai (Malaysia)

Dr Jacqueline Dominguez (Philippines)

Dr Vorapun Senanarong (Thailand)

***ASCEND2 in the Management of Mild Cognitive Impairment (Part 1):***

***– Implications and Window of Opportunities***

***(What are the Key Learnings from ASCEND2?)***



A webinar series brought to you by  
Schwabe Pharma Asia Pacific



**web-BRAIN-nar**  
*BRidging Asia In Neurocognition*

Speaker:

**A/Prof. Dr. Nagaendran Kandiah**

Senior Consultant and Programme  
Director

National Neuroscience Institute (NNI),  
Singapore



Dr Nagaendran Kandiah is a senior consultant neurologist with National Neuroscience Institute (NNI), Singapore. He is also the director of the NNI Dementia Programme. He holds a Clinician Scientist position with the National Medical Research Council of Singapore. He obtained his MBBS in 1998 and subsequently his MRCP. He completed his neurology training in 2007 and underwent a fellowship in cognitive neurology at the University of British Columbia, Canada. His research interest includes Mild Cognitive Impairment, Role of Cerebrovascular disease in Alzheimer's dementia, Parkinson's disease dementia and Frontotemporal Dementia. He holds several national grants investigating these research areas and has published extensively in his field. He is also actively involved in the training aspects of dementia and is currently the chairman of the Neurocognitive and Research Training Consortium of Southeast Asia (NRTC-SEA). From a clinical perspective he has vast experience in the diagnosis and management of Alzheimer's disease, Vascular dementia, Frontotemporal dementia, Autoimmune dementia and other related dementias. He has a special interest in Young Onset Dementia and leads the Singapore Ministry of Health initiative on Comprehensive Young Onset Dementia Programme. He is also the chairman of the Singapore, Ministry of Health, Clinical Practice Guidelines on Dementia..



A webinar series brought to you by  
Schwabe Pharma Asia Pacific



# web-BRAIN-nar

*BRidging Asia In Neurocognition*

## Synopsis

Mild Cognitive Impairment (MCI) is one of the top 10 chronic disorders worldwide and is projected to increase to be among the top 3 chronic disease worldwide by 2030. MCI is a high-risk state for progression to dementia with an annual progression rate of 12-15%. While the aetiology of MCI is multifactorial, Alzheimer's disease and cerebrovascular disease are major pathologies contributing to MCI. Biomarker evidence suggest that amyloid-tau pathology and cerebrovascular pathology to be prevalent among elderly MCI subjects of the amnestic type. MCI presents a golden window of opportunity for the prevention of Alzheimer's dementia and vascular dementia. In this presentation, the epidemiology, classification, clinical-cognitive presentation and biomarker profile of MCI will be discussed. The evidence from pharmacological and non-pharmacological clinical trials for the management of MCI will be presented with special focus on the recommendations from the ASCEND2 expert consensus publication (Kandiah N et al. CNS Neurosci Ther. 2020;00:1–14) on the strategies for the use of Ginkgo biloba extract, EGb 761<sup>®</sup>, in the treatment and management of MCI in Asia.